PACB vs. CRSP
PACB (Pacific Biosciences of California, Inc.) and CRSP (CRISPR Therapeutics AG) are both stocks. Both are in the Healthcare sector — PACB in Diagnostics & Research, CRSP in Biotechnology. Over the past 5 years, PACB returned -46.94%/yr vs -16.09%/yr for CRSP. At a 0.42 correlation, their price movements are largely independent.
Performance
PACB vs. CRSP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PACB achieves a -29.41% return, which is significantly lower than CRSP's 3.66% return.
PACB
- 1D
- -5.71%
- 1M
- 8.20%
- YTD
- -29.41%
- 6M
- -27.47%
- 1Y
- 3.94%
- 3Y*
- -52.73%
- 5Y*
- -46.94%
- 10Y*
- -16.62%
CRSP
- 1D
- 0.50%
- 1M
- 7.94%
- YTD
- 3.66%
- 6M
- -6.13%
- 1Y
- 22.85%
- 3Y*
- -1.00%
- 5Y*
- -16.09%
- 10Y*
- —
PACB vs. CRSP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PACB Pacific Biosciences of California, Inc. | -29.41% | 2.19% | -81.35% | 19.93% | -60.02% | -21.13% | 404.67% | -30.54% | 180.30% | -30.53% |
CRSP CRISPR Therapeutics AG | 3.66% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 151.39% | 113.18% | 21.68% | 15.89% |
Correlation
The correlation between PACB and CRSP is 0.41, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.41 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.45 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.51 |
Correlation (All Time) Calculated using the full available price history since Oct 19, 2016 | 0.42 |
The correlation between PACB and CRSP has been stable across timeframes, ranging from 0.41 to 0.51 - a consistent structural relationship.
Fundamentals
PACB:
$403.68M
CRSP:
$5.22B
PACB:
-$0.43
CRSP:
-$6.24
PACB:
2.49
CRSP:
1.21K
PACB:
3.85
CRSP:
2.88
PACB:
$160.03M
CRSP:
$4.10M
PACB:
$59.34M
CRSP:
-$171.17M
PACB:
-$146.34M
CRSP:
-$509.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PACB vs. CRSP — Risk / Return Rank
PACB
CRSP
PACB vs. CRSP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PACB | CRSP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.32 | ||
| Sortino ratioReturn per unit of downside risk | -0.25 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.11 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 0.07 | 0.54 | -0.48 |
| Martin ratioReturn relative to average drawdown | 0.13 | 0.89 | -0.76 |
Loading charts...
Drawdowns
PACB vs. CRSP - Drawdown Comparison
The maximum PACB drawdown since its inception was -98.22%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for PACB and CRSP.
Loading charts...
Drawdown Indicators
| PACB | CRSP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.22% | -85.11% | -13.11% |
Max Drawdown (1Y)Largest decline over 1 year | -58.05% | -42.25% | -15.80% |
Max Drawdown (3Y)Largest decline over 3 years | -93.47% | -64.91% | -28.56% |
Max Drawdown (5Y)Largest decline over 5 years | -97.47% | -80.68% | -16.79% |
Max Drawdown (10Y)Largest decline over 10 years | -98.22% | — | — |
Current DrawdownCurrent decline from peak | -97.42% | -74.12% | -23.30% |
Average DrawdownAverage peak-to-trough decline | -70.56% | -49.29% | -21.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.43% | 25.88% | +5.55% |
Volatility
PACB vs. CRSP - Volatility Comparison
Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 22.70% compared to CRISPR Therapeutics AG (CRSP) at 17.92%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PACB | CRSP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.70% | 17.92% | +4.78% |
Volatility (6M)Calculated over the trailing 6-month period | 56.28% | 43.95% | +12.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 87.66% | 62.70% | +24.96% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.45% | 60.72% | +33.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 84.72% | 64.31% | +20.41% |
Dividends
PACB vs. CRSP - Dividend Comparison
Neither PACB nor CRSP has paid dividends to shareholders.
Financials
PACB vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
PACB and CRSP have a correlation of 0.41, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PACB has higher volatility (22.70%) compared to CRSP (17.92%). In terms of maximum drawdown, PACB dropped -98.22% vs CRSP's -85.11%.
CRSP currently has the higher Sharpe Ratio (0.37 vs 0.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PACB and CRSP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer